Shorts

1:26
Emerging Targeted Therapies for Myasthenia Gravis
3 months ago
by
Isabella Ciccone, MPH(+1 more)

1:33
Design Considerations for Stem-Cell Based MS Trials
3 months ago
by
Jeffrey Cohen, MD(+1 more)

1:06
Phase 3 Updates for MASCOT Trial of MSA Agent Amlenetug
4 months ago
by
Marco Meglio(+1 more)

0:44
Why Pediatric Stroke Collaboration Matters
4 months ago
by
Beth Cavanaugh, MD(+1 more)

1:06
Understanding Mechanism of Investigational Lu AF28996 in Parkinson Disease
4 months ago
by
Marco Meglio(+1 more)

1:18
Recapping the 2026 ACTRIMS Forum
4 months ago
by
Isabella Ciccone, MPH(+1 more)

1:06
FDA Approval of High-Dose Nusinersen for Spinal Muscular Atrophy
4 months ago
by
Marco Meglio(+1 more)

1:25
Living a Full Life with MS: Finding Hope and Specialized Care
4 months ago
by
Constance V. Katsafanas, DO(+1 more)

1:07
Treating RLS Without Drug Interactions
4 months ago
by
Louie Pasculli(+1 more)

0:45
MS Roundtable: Educational Changes Needed With New Diagnostic Criteria
4 months ago
by
Marco Meglio(+1 more)

1:17
MS Roundtable: Treating Multiple Sclerosis Before Symptoms Arise
4 months ago
by
Marco Meglio(+1 more)

1:17
MS Roundtable: Top Takeaways From 2024 McDonald Criteria
4 months ago
by
Marco Meglio(+1 more)

1:17
Purple Day: Exciting, Novel Treatments on the Horizon for Epilepsy
4 months ago
by
Marco Meglio(+1 more)

0:35
Overviewing Phase 3 DAWN Efficacy Data of Daratumumab in NMOSD
4 months ago
by
Michael Levy, MD, PhD(+1 more)

0:58
Why Some RLS Medications Can Make Symptoms Worse
4 months ago
by
Louie Pasculli

1:33
Meeting the Needs of Underserved Multiple Sclerosis Populations
4 months ago
by
Marisa McGinley, DO(+1 more)

0:37
Early Identification and Newborn Screening for Neuromuscular Disorders
4 months ago
by
John F. Brandsema, MD(+1 more)

2:00
Data Behind EBNA1 Antibodies as Distinguishable Feature of Multiple Sclerosis
4 months ago
by
Marco Meglio

1:10
4 FDA-Approved Treatments for NMOSD You Should Know
4 months ago
by
Louie Pasculli

1:24
Clinical Value of EBNA1 Antibodies in MS, MOGAD, & NMOSD
4 months ago
by
Marco Meglio

1:01
Emerging CAR-T Therapy Approaches in NMOSD
4 months ago
by
Louie Pasculli

0:31
Addressing Access Barriers to Emerging Therapies in Neuromuscular Disease
4 months ago
by
Isabella Ciccone, MPH(+1 more)

1:33
Developing Pivotal Trials for Stem Cell-Based Agents in Multiple Sclerosis
4 months ago
by
Jeffrey Cohen, MD(+1 more)

0:48
MDA 2026: Accepting the MDA Legacy Award
4 months ago
by
Allison Moore(+1 more)

1:02
How Deramiocel Works
4 months ago
by
Noah Stansfield

0:51
Research and Collaboration in Neuromuscular Medicine
4 months ago
by
Marco Meglio(+1 more)

0:51
MDA 2026: Receiving the MDA Legacy Award
4 months ago
by
Michio Hirano, MD(+1 more)

0:51
MDA 2026: Future Vision of Neuromuscular Disorders
4 months ago
by
Isabella Ciccone, MPH(+1 more)

0:31
MDA 2026: Phase 2 ALKIVIA Study
4 months ago
by
Isabella Ciccone, MPH(+1 more)

0:47
MDA 2026: In the Shoes of the Patient
5 months ago
by
Isabella Ciccone, MPH(+1 more)
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
The Expanding Role of Blood-Based Biomarkers in Alzheimer Disease
2
Advances in Fragile X Syndrome Therapeutics: Overviewing the Pipeline
3
The Role of Cerebrospinal Fluid in Personalized Alzheimer Disease Care: Betty Tijms, PhD
4
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
5
